Trevi Therapeutics, Inc. (TRVI) Form 8-K — Jun 4, 2026
Trevi Therapeutics held its 2026 Annual Meeting of Stockholders on June 3, 2026, where shareholders approved several routine corporate governance proposals. Michael Heffernan was elected to the Board of Directors as a Class I director, receiving over 81 million votes in favor. Shareholders also approved an amendment to the company’s Restated Certificate of Incorporation, increasing the number of authorized common shares from 200 million to 400 million. This increase provides the company with greater flexibility for future equity issuances, such as stock-based compensation or potential capital raises.
Key figures
- Votes for auditor
- 114,001,970
- Votes for director
- 81,567,765
- Stock plan increase
- 8,000,000
- Votes for say on pay
- 98,119,461
- Votes for stock plan
- 98,140,470
- Authorized shares pre
- 200,000,000
- Votes against auditor
- 223,323
- Authorized shares post
- 400,000,000
- Votes against director
- 18,635,726
- Votes against say on pay
- 1,982,126
- Votes against stock plan
- 1,961,030
- Votes for share increase
- 110,453,620
- Votes against share increase
- 3,872,599
Price after filing
Close on the filing date to close N calendar days later (from $13.93). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.